Acrux will proceed to file a marketing application in Europe, under the brand name Ellavie. Acrux said that it has already received strong commercial interest for Ellavie from potential marketing partners in the ex-US pharmaceutical markets.
Evamist was originally licensed by Acrux to Vivus, which subsequently sub-licensed rights to KV. With Acrux’s consent, Vivus has assigned the licence to KV and KV is now Acrux’s licensee.
Under the new agreement, KV has licensed Acrux’s transdermal spray technology for application in six additional products, with the potential to add further products in the future.
Three preclinical products, including a combination hormone therapy Duomist, have been licensed for the US market only. KV will fund all clinical development costs for each product and Acrux will receive royalties on US sales plus milestone payments. Acrux will have access to the data contained in KV’s FDA filings for regulatory filings in all other territories. In return, Acrux will pay to KV a share of its licensing revenues from those territories.
The technology has further been licensed to KV to develop three novel
products for global markets. KV will fund all clinical development costs for
each product and Acrux will receive royalties on global sales plus milestone
payments.
Richard Treagus, CEO of Acrux, said: “The collaboration with KV not only allows us to proceed immediately with the commercialisation of our estradiol product in the major markets outside the US, but just as importantly it aligns us strongly with a very capable and committed marketing partner. I am delighted that, following the launch of Evamist, KV has seen the value and potential in our unique spray technology.”